Purple biotech reports second quarter 2024 financial results and business highlights

Positive randomized phase 2 cm24 pancreatic cancer study interim data presented at the american society of clinical oncology ( asco) 2024 annual meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in the combination of cm24+nivolumab and nal-iri/5fu/lv chemotherapy cohort
PPBT Ratings Summary
PPBT Quant Ranking